Jennifer Doudna’s Scribe Therapeutics lands a $100M Series B to advance CRISPR technology
San Francisco Business Times
|
March 31, 2021
X min read
San Francisco Business Times
|
March 31, 2021
Share on Social
More like this
Media
Another proof point from CIRM-supported research
October 7, 2026
California Institute for Regenerative Medicine
Read Now
Press
Another proof point from CIRM-supported research
October 7, 2026
California Institute for Regenerative Medicine
Read Now
